Find more articles and bullets on these widgets:
Reeves on UK-US deal on drug pricing which is reported to cost an extra GBP3bln/year: "That was part of the agreement in the Spending Review that... would be absorbed. The costs are actually quite low in the first couple of years... But obviously at future spending obviously, everything in the next spending review will be set out in the next spending review.
This has been running faster as Market Participants favoured to start rolling early ahead of Today's FOMC. Expiry is Monday 15th.
The hawkish repricing derived from moves on the EUR strip has led to the belly selling off on the 2-/5-/10-Year gilt butterfly.
Fig. 1: UK 2-/5-/10-Year Butterfly (bp)

Source: MNI - Market News/Bloomberg Finance L.P.